期刊文献+

抗前列腺癌新药卡巴他赛的药理与临床评价 被引量:13

Pharmacology and clinical evaluation of antiprostate cancer cabazitaxel
原文传递
导出
摘要 卡巴他赛(cabazitaxel)属于紫杉烷类抗肿瘤药,主要用于治疗激素难治性转移性前列腺癌。文中利用PUBMED对关键词cabazitaxel进行检索,并对其药理作用、作用机制、药动学、临床评价等进行综述。 Cabazitaxel,a novel tubulin-binding taxane,is used to treat hormone-refractory metastatic prostate cancer.Literature search was conducted using PUBMED with the kew word cabazitaxel.The pharmacology,pharmacokinetics and clinical evaluations were reviewed.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第9期763-765,共3页 Chinese Journal of New Drugs
关键词 卡巴他赛 激素难治性转移性前列腺癌 药理学 药动学 临床评价 cabazitaxel hormone-refractory metastatic prostate cancer pharmacology pharmacokinetics clinical evaluation
  • 相关文献

参考文献9

  • 1JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2009 [J]. CA Cancer JClin, 2009, 59(4): 225 -249.
  • 2孙颖浩.我国前列腺癌的研究现状[J].中华泌尿外科杂志,2004,25(2):77-80. 被引量:355
  • 3PETRYLAK DP, TANGEN CM, HUSSAIN MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [ J ]. N Engl J Med, 2004, 351(15) : 1513 -1520.
  • 4BERRY DL, MOINPOUR CM, JIANG CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone[ J]. J Clin Oncol, 2006, 24(18) : 2828 -2835.
  • 5Jevtana [ EB/OL ].[ 2010 - 11 - 02 ]. http ://www. accessdata. fda. gov/drugsatfda_docs/label/2010/2010231bl, pdf.
  • 6Sanofi-aventis. XRP6258 investigator's brochure[ M]. Antony (France) : Sanofi-aventis,2000.
  • 7ATTARD G, GREYSTOKE A, KAYE S, et al. Update on tubulin binding agents [ J ]. Pathol Biol( Paris), 2006, 54 ( 2 ) : 72 - 84.
  • 8PIVOTI X, KORALEWSKI P, HIDALGO JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008, 19(9) : 1547 -1552.
  • 9SEBASTIAN J, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic astration-resistant prostate cancer progressing after ocetaxel treatment: a randomised open-label trial [ J ]. Lancet, 2010, 376 ( 9747 ) : 1147 - 1154.

共引文献354

同被引文献96

引证文献13

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部